CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
A

Triglycerides

Lipids & LipoproteinsLab test / biomarkerriskmodifiablegenetic-causal
91
evidence score

Also known as: hypertriglyceridemia, increased triglycerides, plasma triglycerides, triglyceride, triglyceride levels, triglycerides (TGs), triglycerides (elevated), triglycerides ≥200 mg/dL, triglycerides, 115.8 mg/dL

PREVENT status

Not a PREVENT input variable.

Causal support

genetic causal candidate

Score components
lit volume: 25.9meta-analyses: 20trials: 15genetic: 20MR bonus:
Associated genes
ANGPTL4APOA5APOC3LPLTRIB1

References (389)

28 meta-analyses / systematic reviews

Clinical trials (138)

showing top 60
NCTTitleStatusTypeInterventions
NCT07198789Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial to Evaluate the Effect of a Functional Low-Glycemic Index Carbohydrates Versus Standard Wholegrain Carbohydrates on Glycolipid Metabolism and Vascular Stress Markers in Subjects With Suboptimal TriglyceridemiaRECRUITINGINTERVENTIONALAltograno® Bakery Foods, Standard Whole-Grain Bakery Foods
NCT07004777Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition in Individuals With Hypertriglyceridemia. Controlled Clinical Trial.RECRUITINGINTERVENTIONALIsocaloric diet including chia and pumpkin seeds, Isocaloric diet
NCT06988462Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" FoodRECRUITINGINTERVENTIONALBottarga, Comparator
NCT06764082Nutritional Intervention With High Chain Triglyceride Formulation During Perioperative Period of Kasai Surgery for Biliary Atresia: a Prospective Multicenter TrialRECRUITINGINTERVENTIONALhigh MCT formula, normal oral intake of the traditional formula
NCT05937789Effects of Early Vitamin D3 Supplementation on Clinical Outcomes for Critically Ill PatientsRECRUITINGINTERVENTIONALVitamin D3, Medium Chain Triglycerides (MCT)
NCT03875625Change of Adipose Tissues and Triglyceride in Obese Patients With Non-alcoholic Fatty Liver Disease After Bariatric Surgery or Life-style InterventionRECRUITINGINTERVENTIONALBariatric surgery, Dietitian led life style modification intervention, Conventional care (control)
NCT07394517Efficacy of Phospholipid Omega-3 (Ruby-O) Versus Conventional Omega-3 on the Omega-3 Index in Patients With Mixed Dyslipidemia: A 24-Week Randomized, Double-Blind, Parallel TrialNOT YET RECRUITINGINTERVENTIONALPhospholipid Omega-3, Phospholipid Omega-3, Triglyceride Omega-3
NCT07241377A Randomized, Double-blind Placebo-controlled Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources in Natural Triglyceride Form to One Fish Source in Re-esterified Triglyceride Form (GOBO 2 Study)ACTIVE NOT RECRUITINGINTERVENTIONALlife'sTM omega O1035DS nTG, life'sTM omega O3020DS nTG, MEG-3 3323rTG
NCT06640972A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of ObesityCOMPLETEDINTERVENTIONALRDX-002, Placebo
NCT06588972Analgesic Effects of a Treatment With Cannabis Sativa Extract in Patients With Knee Osteoarthritis - CANOA (Cannabis for Osteoarthritis)COMPLETEDINTERVENTIONALMedium Chain Triglyceride solution, Cannabis Sativa
NCT05874141Comorbidities in Type 2 Diabetes Mellitus: An Observational Study in Kharga City, New Valley Governate, EgyptCOMPLETEDINTERVENTIONALHBA1C, Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides, Urine analysis and urinary albumin-to-creatinine ratio
NCT06013761Monocentric Randomized Experimental Pilot Trial Investigating the Influence of Intermittent Fasting According to the 16:8 Method With and Without Medium-chain Triglycerides (MCTs) on Seizure Frequency, Biomarkers and Neural Networks in Patients With Drug-resistant EpilepsyCOMPLETEDINTERVENTIONALIF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm
NCT05933200A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared With Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)ACTIVE NOT RECRUITINGINTERVENTIONALTriheptanoin, MCT Oil
NCT05193916A Multi-Center, Randomised, Double-blind, Placebo Controlled Phase II Clinical Study of Chiglitazar in Patients With Nonalcoholic Steatohepatitis Accompanied by Elevated Triglycerides and Insulin ResistanceCOMPLETEDINTERVENTIONALchiglitazar sodium tablets, Placebo
NCT06154408Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms: A Randomized, Double-blind, Placebo-controlled TrialCOMPLETEDINTERVENTIONALomega-3 fatty acids, Placebo
NCT05178550An Open-label, Randomized, Single Center, Crossover Study in Healthy Participants to Assess Lipoprotein Lipase Activity and Levels, and Triglyceride Levels After Heparin Exposure, in Both Fasted and Postprandial StateCOMPLETEDINTERVENTIONALHeparin
NCT05079919A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe HypertriglyceridemiaCOMPLETEDINTERVENTIONALOlezarsen, Placebo
NCT04905589Effect of Combined Intake of Medium Chain Triglycerides (MCT) At Breakfast and Whey Protein Isolate (WPI) Preload At Lunch and Dinner on Diurnal Glucose and SatietyCOMPLETEDINTERVENTIONALBetaQuik™, WheyBasics, Iso-voluminous water
NCT04662411Butyrate/Hexanoate-enriched Triglycerides for Metabolic HealthCOMPLETEDINTERVENTIONALPlacebo, butyrate and hexanoate amount 1, butyrate and hexanoate amount 2
NCT04675255WU 360: Assessing the Impact of Integrase Strand Transfer Inhibitors (INSTI) to Protease Inhibitor (PI) Switch on Insulin Sensitivity and Fat Metabolism (ADIPOSITY): a Sub-study of DEFINECOMPLETEDINTERVENTIONALFrequently sampled glucose tolerance testing, abdominal subcutaneous adipose tissue biopsy, MRI scan to assess intrahepatic triglyceride content
NCT04459767A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07285557 (VUPANORSEN) ADMINISTERED SUBCUTANEOUSLY IN JAPANESE HEALTHY ADULTS WITH ELEVATED TRIGLYCERIDESCOMPLETEDINTERVENTIONALVupanorsen, Placebo
NCT04412018An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19)COMPLETEDINTERVENTIONALIcosapent ethyl
NCT04239950A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ethyl Icosapentate in Patients With Severe HypertriglyceridemiaCOMPLETEDINTERVENTIONALPlacebo, Ethyl Icosapentate
NCT04321018Effect of the Addition of Medium Chain Triglycerides to a Mixed Macronutritional Meal on the Oxidation of Postprandial MacronutrientsUNKNOWNINTERVENTIONALMixed meal with medium chain triglycerides, Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides
NCT04140201Evaluation of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic PatientsUNKNOWNINTERVENTIONALSimvastatin 40mg, Fenofibrate 200mg, Omega 3 fatty acid
NCT04307979Impact of Bulletproof Coffee on Metabolism, Inflammation and Cognitive FunctionUNKNOWNINTERVENTIONALHigh-fat coffee, Black coffee
NCT03661047OMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal CancerWITHDRAWNINTERVENTIONALAMR101 (VASCEPA, icosapent ethyl)
NCT04152291The Effect of Ethyl Eicosapentaenoic Acid on Circulating Low-density Lipoproteins and Plasma Lipid Metabolism in Healthy VolunteersCOMPLETEDINTERVENTIONALEthyl-Eicosapentaenoic Acid (E-EPA)
NCT04042142In-depth Studies of Glucagon Resistance on Hepatic Glucose, Fatty Acid and Triglyceride Kinetics and Generation of Toxic Lipid Intermediates in NAFLD and NASH.COMPLETEDINTERVENTIONALglucagon
NCT04095728A Randomized, Double-blind, Placebo-controlled, Parallel Study Investigating the Efficacy of Brain Octane® Oil (Caprylic Acid Triglycerides) on Cognition, Coordination, Reaction Time and Measurements of Physical Performance in Recreationally Active AdultsCOMPLETEDINTERVENTIONALBrain Octane Oil, Placebo
NCT04448067Dietary Incorporation of Lentils to Improve Metabolic HealthCOMPLETEDINTERVENTIONALDietary Lentil Intake, No Dietary Lentil CONTROL
NCT03510715An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaCOMPLETEDINTERVENTIONALAlirocumab SAR236553 (REGN727), Atorvastatin, Simvastatin
NCT03510884A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaCOMPLETEDINTERVENTIONALAlirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin
NCT03528252Effectiveness of Written Dietary Advice on Lipoproteins - a Pragmatic Randomized Controlled Trial (MYDICLIN)COMPLETEDINTERVENTIONALWritten advice LDL Cholesterol, Written advice Triglycerides
NCT04987567Effect of Antioxidant Docosahexaenoic Acid (DHA) Supplementation in Cystic Fibrosis Patients: A Randomized Placebo-controlled TrialCOMPLETEDINTERVENTIONALANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®), PLACEBO (OLIVE OIL)
NCT03828188A 12-week, Randomized, Double-blind, Placebo-controlled 2x2 Cross-over Design Human Trial to Evaluate the Efficacy and Safety of Red Ginseng Concentrated Powder on Improvement of Blood Triglyceride LevelCOMPLETEDINTERVENTIONALRed Ginseng Concentrated Powder, Placebo
NCT03361501A Phase 3, Multi-center, Multi-national, Placebo-controlled, Randomized, Double-blind 26 Week Study to Assess the Safety and Efficacy of CaPre® in Patients With Severe HypertriglyceridemiaCOMPLETEDINTERVENTIONALCaPre, Placebo
NCT03830268Optimisation of Acute Medium Chain Triglycerides Intake Characteristics on Different Plasma Metabolites in Young and Older ParticipantsCOMPLETEDINTERVENTIONALNo MCT intake with breakfast, no lunch, No MCT intake with lunch, no breakfast, 10g of Betaquik
NCT02926027Effect of Vascepa on Progression of Coronary Atherosclerosis in Persons With Elevated Triglycerides (200-499) on Statin TherapyCOMPLETEDINTERVENTIONALVascepa, placebo
NCT03071692Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)TERMINATEDINTERVENTIONALK-877, Placebo
NCT03378232EPA and DHA Regulation of Blood Triglycerides, Resting Metabolic Rate and Blood Markers of Cardiometabolic Health.COMPLETEDINTERVENTIONALPlacebo Olive Oil, High EPA Supplement, High DHA Supplement
NCT03001817A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Normal Renal FunctionCOMPLETEDINTERVENTIONALK-877, Fenofibrate, Placebo (for K-877)
NCT02984982A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, Parallel Group, Multicenter Study to Evaluate the Effect of Praluent® (Alirocumab) on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Not Adequately Controlled With StatinCOMPLETEDINTERVENTIONALAlirocumab SAR236553, Atorvastatin, Rosuvastatin
NCT02890992An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension PhaseCOMPLETEDINTERVENTIONALalirocumab SAR236553 (REGN727), statins, ezetimibe
NCT02833012A Phase 1, Pilot, Single-Dose, 4-Way Crossover Study to Compare the Pharmacokinetics of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body ProductionCOMPLETEDINTERVENTIONALCaprylic Triglyceride Oil, AC-1202, Axona
NCT02825745A Feasibility Study of the Use of Betashot, a Medium Chain Triglyceride- Based (MCT) Food for Special Medical Purposes (FSMP) in Children and Adults With Epilepsy.COMPLETEDINTERVENTIONALBetashot
NCT02773381A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 DiabetesCOMPLETEDINTERVENTIONALsemaglutide, placebo
NCT02721277Compassionate Use of an Intravenous Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil for Neonates With Parenteral Nutrition Induced Liver InjuryTERMINATEDINTERVENTIONALSMOFlipid
NCT02642159A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin TherapyCOMPLETEDINTERVENTIONALAlirocumab, Statins, Ezetimibe
NCT02611102Effects of Daily Butter & Medium-Chain Triglyceride Oil on Lipoproteins When Added to Baseline Diet a Randomized Controlled TrialCOMPLETEDINTERVENTIONALMCT oil + Butter in Coffee
NCT02681055An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With HypertriglyceridemiaCOMPLETEDINTERVENTIONALMN-001
NCT02802904Multicountry Studies on the Effect of Positional Distribution of Fatty Acids at Triglyceride Backbone on Serum Lipids, Lipoprotein(a) and LDL-subclasses in Healthy Malaysian VolunteersCOMPLETEDINTERVENTIONALDiet: Palm olein IV64, Diet: Cocoa butter, Diet: Virgin olive oil
NCT02797483Multi-country Studies on the Effect of Positional Distribution of Fatty Acids at the Triglyceride Backbone of Vegetable Oils on Fat Deposition and Selected Health Outcome Measures - MalaysiaCOMPLETEDINTERVENTIONALTest Fat Blue, Test Fat Green, Test Fat Red
NCT02709850A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered Subcutaneously to Healthy Volunteers With Elevated Triglycerides and Subjects With Familial HypercholesterolemiaCOMPLETEDINTERVENTIONALIONIS ANGPTL3-LRx, Placebo
NCT02678390Stimulating the Production of Ketones Through the Combined Use of Aerobic Exercise (AE) and Dietary a Medium Chain Triglycerides (MCT) SupplementCOMPLETEDINTERVENTIONALMCT, MCT+ aerobic exercise, Aerobic exercise
NCT02679222Comparing the Ketogenic Effect of Coconut Oil and Different Medium-chain TriglyceridesCOMPLETEDINTERVENTIONALCoconut oil, Coconut oil + MCT, MCT
NCT02455336An Open Label Safety and Efficacy Trial of Fenofibrate in Persons With SCICOMPLETEDINTERVENTIONALFenofibrate, No intervention
NCT02332434Effects of Various Bariatric Surgical Procedures on Intestinal Triglyceride-rich-lipoprotein (TRL) Metabolism in Obese Type 2 Diabetic PatientsUNKNOWNINTERVENTIONALstable isotope enrichment methodology (5,5,5-D3-L-Leucine)
NCT02426047The Feasibility and Tolerability of Medium Chain Triglycerides as an Adjunct to the Dietary Management of Epilepsy in Women With a Catamenial Seizure Pattern on the Modified Atkins DietCOMPLETEDINTERVENTIONALbetaquik®
NCT02376621Nutrition Products - An Open-Label, Randomised, Single-Dose Study to Evaluate the Bioavailability of Omega-3 Based Dietary Supplements Under Fasting Conditions in Healthy Male and Female SubjectsCOMPLETEDINTERVENTIONALPronovaPure 150:500 triglycerides, Pronovum PRF-048, Pronovum PRF-037

Genetic associations (563)

showing top 80 by significance
VariantGene(s)TraitpOR/βStudy
LPL1e-1504—GCST90239661
LPL1e-1198—GCST90239649
LPL1e-11000.22 % increaseGCST90501245
LPL1e-10290.22 % increaseGCST90501193
LPL1e-10050.21 ratio increaseGCST90501273
LPL1e-10010.21 % increaseGCST90501145
LPL1e-9160.2 % decreaseGCST90501183
LPL1e-8970.21 mmol/L increaseGCST90501268
LPL1e-8920.2 % decreaseGCST90501199
LPL1e-8830.179736 unit decreaseGCST90239664
LPL1e-8200.19 % increaseGCST90501305
LPL1e-8060.2 % decreaseGCST90501185
LPL1e-7880.19 % decreaseGCST90501151
APOC31e-7871.2616 unit decreaseGCST90025957
LPL1e-7620.19 mmol/L increaseGCST90501244
LPL1e-7620.18 nm increaseGCST90501292
LPL1e-7600.19 % decreaseGCST90501251
LPL1e-7310.1871 unit decreaseGCST90018975
LPL1e-7190.11 mmol/L increaseGCST90501113
LPL1e-7150.18 % increaseGCST90501219
LPL1e-6780.18 mmol/L increaseGCST90501293
LPL1e-6720.11 mmol/L increaseGCST90501112
LPL1e-6700.18 % increaseGCST90501257
LPL1e-6670.18 mmol/L increaseGCST90501316
LPL1e-6660.18 % decreaseGCST90501122
LPL1e-6650.18 mmol/L increaseGCST90501282
LPL1e-6650.17 % decreaseGCST90501321
LPL1e-6620.18 mmol/L increaseGCST90501338
LPL1e-6590.18 mmol/L increaseGCST90501166
LPL1e-6570.18 mmol/L increaseGCST90501334
LPL1e-6500.18 mmol/L increaseGCST90501313
LPL1e-6440.18 mmol/L increaseGCST90501330
LPL1e-6360.18 mmol/L increaseGCST90501165
LPL1e-6320.107166 unit increaseGCST90239652
LPL1e-6300.18 mmol/L increaseGCST90501312
LPL1e-6240.17 % decreaseGCST90501267
LPL1e-6220.17 mmol/L increaseGCST90501337
LPL1e-6190.18 mmol/L increaseGCST90501332
LPL1e-6190.15 mmol/L decreaseGCST90501136
LPL1e-6190.18 mmol/L increaseGCST90501216
LPL1e-6190.17 % decreaseGCST90501319
LPL1e-6170.18 mmol/L increaseGCST90501164
LPL1e-6170.17 mmol/L increaseGCST90501328
LPL1e-6160.17 % decreaseGCST90501263
LPL1e-6140.17 mmol/L increaseGCST90501168
LPL1e-6040.17 mmol/L increaseGCST90501314
LPL1e-5980.15 mmol/L decreaseGCST90501134
LPL1e-5950.11 mmol/L increaseGCST90501184
LPL1e-5930.17 mmol/L increaseGCST90501162
LPL1e-5840.16 % increaseGCST90501191
LPL1e-5780.16 % decreaseGCST90501209
LPL1e-5780.17 mmol/L increaseGCST90501310
LPL1e-5760.17 mmol/L decreaseGCST90501119
LPL1e-5760.1194 unit increaseGCST90018956
LPL1e-5730.1 mmol/L increaseGCST90501182
LPL1e-5680.16 % increaseGCST90501132
LPL1e-5610.16 ratio decreaseGCST90501230
LPL1e-5580.17 mmol/L increaseGCST90501336
LPL1e-5560.17 mmol/L increaseGCST90501256
LPL1e-5460.16 % increaseGCST90501329
LPL1e-5450.11 % decreaseGCST90501327
LPL1e-5230.15 % decreaseGCST90501135
LPL1e-5160.15 % decreaseGCST90501207
LPL, RPL30P91e-5150.13 mmol/L increaseGCST90501140
LPL1e-5130.09 mmol/L increaseGCST90501142
LPL1e-5120.16 mmol/L increaseGCST90501158
LPL1e-5090.1 % increaseGCST90501124
LPL, RPL30P91e-5090.174 unit decreaseGCST90019523
LPL1e-5040.15 % decreaseGCST90501137
LPL1e-5000.14 mmol/L decreaseGCST90501138
LPL1e-5000.16 % increaseGCST90501235
APOC31e-5000.992167 unit increaseGCST90025956
LPL1e-4970.16 mmol/L decreaseGCST90501192
LPL, RPL30P91e-4780.1312 unit increaseGCST90019510
LPL1e-4770.15 mmol/L increaseGCST90501340
LPL1e-4770.16 mmol/L increaseGCST90501306
LPL1e-4740.13 % decreaseGCST90501187
LPL, RPL30P91e-4730.12 mmol/L increaseGCST90501141
LPL1e-4680.15 % increaseGCST90501269
LPL1e-4640.1 % decreaseGCST90501167